A61K 40/4246
Telomerase or [telomerase reverse transcriptase [tert]
Official title: {Telomerase or [telomerase reverse transcriptase [TERT]}
A61K40/4246 (Telomerase or [telomerase reverse transcriptase [tert]) appears on 45 US grants and 83 published applications in this corpus.
Search patents in A61K- Granted patents
- 45
- Published applications
- 83
- Assignees
- 43
- Inventors
- 122
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 0 | 4 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 2 | 1 |
| 2010 | 1 | 2 |
| 2011 | 0 | 3 |
| 2012 | 1 | 3 |
| 2013 | 3 | 2 |
| 2014 | 3 | 5 |
| 2015 | 2 | 3 |
| 2016 | 3 | 4 |
| 2017 | 3 | 8 |
| 2018 | 2 | 6 |
| 2019 | 2 | 5 |
| 2020 | 6 | 5 |
| 2021 | 2 | 3 |
| 2022 | 5 | 5 |
| 2023 | 3 | 9 |
| 2024 | 3 | 2 |
| 2025 | 2 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of obtaining tumor-specific T cell receptors15 Jul 2025US 12,358,967 B2Hryz (Guangzhou) Biotech Co.
- Synthetic immune receptors and methods of use thereof8 Apr 2025US 12,269,859 B2Angeles Therapeutics, Inc.
- Methods for generating engineered human primary blood dendritic cell lines24 Sep 2024US 12,098,387 B2University of Maryland, Baltimore
- Specific binding molecules for hTERT27 Aug 2024US 12,071,467 B2Oslo Universitetssykehus Hf
- Telomerase polypeptide vaccine for treating cancer4 Jun 2024US 11,998,595 B2Ultimovacs ASA
- T-Cell Receptors13 Aug 2026US 2026/0232802 A1Ospedale San Raffaele S.R.L.
- Polynucleotides, polypeptides, cells, and compositions comprising synthetic immune receptors with methods of manufacture and treatment18 Jun 2026US 2026/0167693 A1Angeles Therapeutics, Inc.
- Anti-cancer vaccine composition comprising peptides derived from tumor-associated antigen, and adjuvant consisting of lipopeptide and immunoactive substance, and use thereof9 Jan 2025US 2025/0009861 A1Cha Vaccine Research Institute Co., Ltd
- Methods for generating primary immune cells26 Sep 2024US 2024/0316106 A1AstraZeneca AB
- Methods of obtaining tumor-specific t cell receptors15 Feb 2024US 2024/0052010 A1Hryz Biotech Co.
Most cited
By later US patents
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool110US 8,637,307 B2The Trustees of the University of Pennsylvania · 2014
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool81US 7,745,140 B2The Trustees of the University of Pennsylvania · 2010
- Activation and expansion of T-cells using an engineered multivalent signaling platform69US 7,638,326 B2The Trustees of the University of Pennsylvania · 2009
- Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer47US 6,440,735 B1Geron Corporation · 2002
- Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease9US 7,597,894 B2Dendreon Corporation · 2009